Fresenius stock absorbs a EUR 750 million biopharma deal

Published on 10/04/2026 at 10:10 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Fresenius stock was priced at EUR 43.63 on October 2, 2026, after the group agreed to spend up to EUR 750 million on mAbxience. Q2 revenue rose 6 percent.

Fresenius SE – Fotorealistisch: Modernes Krankenhauszimmer mit Patientenmonitor bei Tageslicht — Fresenius SE & Co. KGaA (ISIN DE0005785604) ist ein internationaler Gesundheitskonzern mit Sitz in Bad Homburg. Das Unternehmen betreibt Krankenhäuser und entwickelt Arzneimittel und Infusionslösungen. Dieses Bild zeigt: Modernes Krankenhauszimmer mit Patientenmonitor bei Tageslicht, Illustration mit AI erstellt.

Fresenius (ISIN DE000FRE5EN2) stock was last at EUR 43.63 on Xetra on October 2, 2026 at 5:36 p.m. CEST, down 0.38 percent from the prior close of EUR 43.80. On October 1, 2026, finanzen.net reported that Fresenius had acquired the remaining 45 percent of mAbxience for total consideration of up to EUR 750 million.

Biopharma deal expands control

The transaction was signed and completed on September 30, 2026, and includes a contingent EUR 50 million payment tied to site approvals. Fresenius had held 55 percent of mAbxience since 2022, so the deal gives Fresenius Kabi full ownership of the biosimilars platform.

The acquisition is expected to be immediately accretive to Group core earnings per share, while Fresenius said its full-year 2026 guidance and 2030 Biopharma ambition remain unchanged, according to finanzen.net. The platform generated more than EUR 320 million in revenue during fiscal year 2025 and operates three production facilities in Spain and Latin America.

Q2 figures raise the earnings bar

Fresenius reported Q2/2026 group revenue of EUR 5,864 million, up 6 percent from EUR 5,571 million in Q2/2025. Group EBIT reached EUR 719 million, 10 percent above the EUR 654 million reported for the prior-year quarter, while the EBIT margin expanded by 60 basis points to 12.3 percent.

Core EPS increased 14 percent year over year to EUR 0.83 from EUR 0.73, and the company lifted its constant-currency full-year 2026 core EPS growth guidance to 10 percent to 15 percent from 5 percent to 10 percent. These figures come from Fresenius in its Q2/2026 results.

Analyst support remains visible: Markets Insider reported on October 1, 2026, that Jefferies maintained a Buy rating and a EUR 55.00 price target. UBS had maintained Buy with a EUR 56.00 target in a report dated September 17, 2026.

Stock stays below yearly high

Fresenius stock traded between EUR 43.31 and EUR 43.96 on October 2, 2026. Its 52-week range was EUR 35.11 to EUR 52.96, placing the reference price EUR 9.33 below the yearly high, while the market capitalization stood at EUR 24.6 billion and volume reached 972,765 shares.

The next scheduled checkpoint is the Q3/2026 conference call on November 4, 2026, listed by Fresenius. For investors, the mAbxience purchase links the raised earnings framework to a larger biopharma platform, while the share price remains below its 52-week high.